Randomized Controlled Clinical Trial Shows Tocomin®SupraBio™ Improves Arterial Compliance

November 24, 2008

2 Min Read
Randomized Controlled Clinical Trial Shows Tocomin®SupraBio™ Improves Arterial Compliance

Carotech is pleased to announce data from a human study recently published in Archives of Pharmacal Research (Sept 2008:31(9), 1212-7) which demonstrated Tocomin®SupraBio™ (a self emulsifying palm tocotrienol complex) was able to reduce arterial stiffness in healthy adults after 2 months oral supplementation.

In this blinded endpoint clinical trial conducted by researchers in The University of Science, Malaysia, 36 healthy volunteers were randomized to receive either the placebo, 50mg, 100mg or 200mg self emulsifying tocotrienol rich vitamin E (Tocovid™SupraBio™, supplied by Hovid Ltd) daily for 2 months. Measures of arterial compliance (carotid femoral Pulse Wave Velocity and Augmentation Index) and other parameters such as blood pressure and serum lipid profiles were taken before and after treatment. Plasma tocotrienols concentration was also measured.

The results showed that treatment with self emulsifying tocotrienol rich vitamin E produced significantly higher plasma concentrations of tocotrienols compared to placebo. After 2 months of supplementation, statistically significant improvement in Augmentation Index (up to 8.7% reduction from baseline) was observed in all the tocotrienols supplemented groups. Significant improvement in Pulse Wave Velocity (up to 10% reduction from baseline) was also seen in subjects who received 100mg and 200mg self emulsifying tocotrienols rich vitamin E. However, treatment has no effect on blood pressure, serum total cholesterol and LDL-cholesterol.

Decreased arterial compliance or increased arterial stiffness is a predictor of cardiovascular events even in healthy individuals. A reduction in both Augmentation Index and Pulse Wave Velocity, as showed by supplementation with self emulsifying palm tocotrienols complex, indicates better arterial compliance, thus reducing the risks of cardiovascular diseases.

“This study showed that tocotrienols reduced arterial stiffness, in addition to other previously reported cardiovascular benefits including cholesterol lowering and antiplatelet effects.” says WH Leong, Vice President of Carotech Inc.

“SupraBio™, the patented self-emulsifying formulation enhances oral absorption of tocotrienols independent of food intake.” adds WH Leong.

About Carotech Ltd
Carotech Ltd, incorporated in 1990, is a public listed company in Malaysia (MESDAQ Board). It is the first and largest producer of natural full spectrum tocotrienol complex (Tocomin® & Tocomin®SupraBio™), natural mixed carotene complex (Caromin®) and phytosterol complex (Stelessterol™) in the world via its patented technology.

Carotech is the only GMP-Certified tocotrienol producer in the world.

Carotech is a subsidiary of Hovid Ltd (www.hovid.com), one of the largest GMP-certified pharmaceutical companies in Malaysia.

Carotech manufactures these products under the tradenames: Tocomin®, Tocomin®SupraBio™, Caromin® and Stelessterol™.

Tocomin®SupraBio™, the main active ingredient used in Tocovid™SupraBio™, is a patented (US Patent No. 6,596,306) self emulsifying palm tocotrienol complex that ensures optimal tocotrienols oral absorption.

Websites: www.carotech.net and www.tocotrienol.org

Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.

You May Also Like